Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: BAY-50-4798, Bayer.

Gunther Hartmann1

  • 1University of Munich, Division of Clinical Pharmacology, Ludwig-Maximilians Clinic, Ziemssenstrasse 1, 80336 München, Germany. gunther.hartmann@medinn.med.uni-muenchen.de

Current Opinion in Molecular Therapeutics
|June 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose Recommendations for Drugs in Patients With Liver Cirrhosis (The ALIVe Study): Protocol for a Multiphase Validation and Consensus Study.

JMIR research protocols·2026
Same author

5'-Triphosphate guanosine RNAs recruit GTP-binding proteins to suppress RIG-I/IFN type I signaling.

Molecular cell·2026
Same author

RIG-I Stimulation Enhances the Effector Function and Proliferation of Primary Human CD8+ T Cells.

International journal of molecular sciences·2026
Same author

Recommendations on Drug Selection and Dose Adjustment for Patients with Liver Cirrhosis: Results from a Multidisciplinary Expert Panel.

Clinical drug investigation·2026
Same author

Poxvirus dsDNA genomes differentially activate AIM2 or NLRP3 inflammasomes in human primary cells.

The EMBO journal·2026
Same author

Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug-Placebo Differences.

Clinical and translational science·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Bayer is developing BAY-50-4798, an IL-2-selective recombinant cytokine, for cancer and HIV treatment. This novel therapy is currently in phase II clinical trials.

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • Interleukin-2 (IL-2) is a cytokine that stimulates immune responses.
  • Standard chemotherapy faces challenges in efficacy and side effects for various cancers and HIV.
  • Targeted cytokine therapies offer potential for improved treatment outcomes.

Purpose of the Study:

  • To evaluate the potential of BAY-50-4798, an IL-2-selective recombinant cytokine, as an adjunct therapy.
  • To explore the efficacy of BAY-50-4798 in treating various cancers and HIV infection.
  • To advance the clinical development of novel immunotherapies.

Main Methods:

  • Development of a selective recombinant cytokine (BAY-50-4798).
  • Preclinical and clinical evaluation of BAY-50-4798's therapeutic potential.

Related Experiment Videos

  • Phase II clinical trials are currently underway.

    • Main Results:

    • BAY-50-4798 demonstrates IL-2 selectivity, suggesting a targeted immune modulation approach.
    • Potential as an adjunct to standard chemotherapy for diverse cancer types.
    • Investigating therapeutic benefits for HIV infection.

    Conclusions:

    • BAY-50-4798 represents a promising targeted immunotherapy candidate.
    • Further clinical trials are essential to confirm its efficacy and safety.
    • This selective cytokine may enhance current treatment paradigms for cancer and HIV.